Immuneering (IMRX)

• Market cap: $55.9M
• 1 day: 9.09%
• 5 days: 10.43%
• 1 month: 2.27%
• 3 months: -18.18%
• 6 months: -37.28%
• Year to date: -18.55%
• 1 year: -34.07%
• 5 years: -89.77%
• 10 years: -89.77%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

11% more funds holding

Funds holding: 38 [Q3] → 42 (+4) [Q4]

0.84% less ownership

Funds ownership: 14.7% [Q3] → 13.86% (-0.84%) [Q4]

14% less capital invested

Capital invested by funds: $10.9M [Q3] → $9.32M (-$1.55M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 567% upside
• Avg. target: $12.50 594% upside
• High target: $13 622% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 33% 1-year accuracy 56 / 170 met price target	567% upside $12	Buy Reiterated	21 Mar 2025
Chardan Capital Geulah Livshits 18% 1-year accuracy 10 / 57 met price target	622% upside $13	Buy Maintained	8 Jan 2025